SPEECH-PROCESSING-SOLUTI
25.6.2024 09:03:32 CEST | Business Wire | Press release
Philips Speech by Speech Processing Solutions, a globally leading innovator in voice technology, has announced that they are taking their cooperation with Sembly AI further by extending their audio recorder range with another three new products. Each new recorder is designed to cover different consumer needs and is equipped with Sembly vouchers for users to experience Sembly's new AI capabilities with a free trial version.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240625566533/en/
Philips VoiceTracer Audio Recorders (Photo: Business Wire)
Excellent audio recording paired with AI technology
"We are delighted to announce that our partnership with Sembly AI opens up new market opportunities by combining the best of both worlds. By providing top-of-the-line audio recorders paired with an AI meeting assistant, we can offer automatic transcriptions, summaries, and action lists for every recording, whether it’s a lecture or a meeting,” explains Dr. Thomas Brauner, CEO of Speech Processing Solutions. “Our innovative solutions enable busy professionals to save time and conduct meetings more efficiently than ever,” he adds.
The new Philips VoiceTracer Audio Recorder DVT4115 and DVT6115, designed for students, boast 3MICs for long-distance recording, ideal for capturing lectures and interviews. Sembly can then transcribe and summarize these recordings. The new Philips VoiceTracer DVT8115, equipped with a 360° microphone, is perfect for recording meeting minutes, with Sembly's easy share function to promptly distribute minutes and action steps to team members. These devices are part of a broader Philips product range, designed to meet diverse recording needs.
Sembly AI offers more than just meeting minutes
The Sembly AI tech startup, founded in 2019, has expanded to offer a wide range of features, including automatic transcription with speaker separation, meeting notes, summaries, and action points. One of the newest innovations is that Sembly AI can now also offer professional AI insights into meetings and conversations, enabling efficient collaboration and streamlined decision-making.
“Our latest AI technology seamlessly integrates with Philips products, adding value whether customers are in the office or on the go. Sembly AI now offers much more than just meeting minutes and we are fully committed to offer new AI services in the coming weeks and months,” explains Gil Makleff, CEO and Co-founder of Sembly AI. “We are proud to collaborate with Philips to enhance the customer experience, empowering users to unlock the full potential of their audio recordings and maximize productivity,” he adds.
These new devices join Philips’ existing portfolio of audio recorders and conference microphones, all compatible with Sembly AI’s software. To discover the entire range of Philips & Sembly products, visit: www.voicetracer.com
About Speech Processing Solutions (SPS):
Speech Processing Solutions (SPS), the global leader in professional dictation solutions, is active in 50+ countries, with over 4 million users and a worldwide network of 1,000+ partners. It develops and markets industry-leading dictation and transcription solutions, automated documentation workflows with speech recognition, as well as award-winning dictation devices, sold under the Philips brand. SPS's mission is to empower every user to be more productive by simplifying their work with smart, voice-based solutions. Headquartered in Vienna, Austria, SPS has regional offices in Australia, Canada, Belgium, France, Germany, the United Kingdom, and the United States.
Follow Us:
LinkedIn: http://www.linkedin.com/company/speech-processing-solutions
YouTube: http://www.youtube.com/philipsdictation
Facebook: https://www.facebook.com/philipsdictation
Instagram: https://www.instagram.com/philips_dictation/
About Sembly AI
Sembly AI is a voice and conversation analytics technology company, focused on bringing the power of natural language processing to professional meeting environments. Sembly’s products can simplify the work life of distributed teams while providing powerful analytics to help teams attend less while getting more done. Sembly AI was founded by CEO Gil Makleff and CPO Artem Koren in 2019. Gil Makleff was CEO of UMT Consulting Group which was acquired by Ernst & Young. Artem Koren was a Senior Manager at Ernst & Young and CTO at Visual Trading Systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625566533/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom